TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

induced functional androgen deficiency or depression? J Endocrinol 2005;185:345-52.
23A.33 Farel C et al. Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients
treated wilth peginterferon alpha-2a and ribavirin. AIDS 2004;18:1805-9.
23A.34 Beuthien W et al. Vasculitic complications of interferon-a treatment for chronic hepatitis C virus infection:
case report and review of the literature. Clin Rheumatol 2005;24:507-15.
23A.35 European Medicines Agency (EMA). European assessment report (EPAR). Intron A, summary of
product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR
_-_Product_Information/human/000281/WC500034679.pdf. Accessed on August 31 st 2010.
23A.36 Schaefer M et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with
chronic hepatitis C. J Hepatol 2005;42:793-8.
23A.37 Kraus MR et al. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon
induced functional androgen deficiency or depression? J Endocrinol 2005;185:345-52.
23A.38 Farel C et al. Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients
treated wilth peginterferon alpha-2a and ribavirin. AIDS 2004;18:1805-9.
23A.39 Beuthien W et al. Vasculitic complications of interferon-a treatment for chronic hepatitis C virus infection:
case report and review of the literature. Clin Rheumatol 2005;24:507-15.
23A.40 Arase Y et al. Significance of ribavirin concentration in combination therapy of interferon and ribavirin
for chronic hepatitis C. Intervirology 2005;48:138-44.
23A.41 Rivkin AM et al. Epoietin alfa for the treatment of combination therapy induced hemolytic anemia in
patients infected with hepatitis C virus. Pharmacotherapy 2005;25:862-75.
23A.42 Taliani G et al. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for
chronic hepatitis C. J Chemother 2005;17:212-4.
23A.43 Doyuk Kartal E et al. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment
of chronic active hepatitis C. Chemotherapy 2005;51:167-9.
23A.44 Hurst EA et al. Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic
hepatitis C. Arch Dermatol 2005;141:865-8.
23A.45 Bini EJ et al. Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with
asthma and chronic hepatitis C. Mayo Clin Proc 1999;74:367-70.
23A.46 European Medicines Agency (EMA). European assessment report (EPAR). Zeffix, summary of product
characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document _library/EPAR_-
_Product_Information/human/000242/WC500048387.pdf. Accessed on August 31 st 2010.
23A.47 Min AD et al. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68.
23A.48 Palumbo E. New drugs for chronic hepatitis B: a review. Am J Ther 2008;15:167-72.
23A.49 European Medicines Agency (EMA). European assessment report (EPAR). Tamiflu, summary of product
characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR _-
_Product_Information/human/000402/WC500033106.pdf. Accessed on August 31 st 2010.
23A.50 Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007;79:1577-86.
23A.51 Centers for Disease Control and Prevention (CDC). Neuraminidase inhibitors for treatment of influenza
A and B infections. Morb Mortal Wkly Rep 1999;48(RR-14):1-9.
23A.52 Gubareva LV et al. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827-35.
23A.53 Harper SA et al. Seasonal influenza in adults and children: diagnosis, treatment, chemoprophylaxis,
and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society
of America. Clin Infect Dis 2009;48:1003-32.
23A.54 Nakamura K et al. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009
H1N1 influenza A infection. Clin Infect Dis 2010;50:e47-9.
23A.55 European Medicines Agency (EMA). European assessment report (EPAR). Synagis, summary of product
characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000257/WC500056908.pdf. Accessed on August 31 st 2010.
23A.56 Cardenas S et al. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev
Anti Infect Ther 2005;3:719-26.
23A.57 European Medicines Agency (EMA). European assessment report (EPAR). Pegasys, summary of
product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR
_-_Product_Information/human/000395/WC500039195.pdf. Accessed on August 31 st 2010.
23A.58 European Medicines Agency (EMA). European assessment report (EPAR). Pegintron, summary of
product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR
_-_Product_Information/human/000280/WC500039388.pdf. Accessed on August 31 st 2010.
23A.59 European Medicines Agency (EMEA). European assessment report (EPAR). Rebetol, summary of
product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR
_-_Product_Information/human/000246/WC500048210.pdf. Accessed on August 31 st 2010.
23A.60 Ito S et al. Exposure of pregnant women to ribavirin contaminated air: risk assessment and recommendations.
Pediatr Infect Dis J 1993;12:2-5.
23A.61 Rendón AL et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic
response in HIV:hepatitis C virus co-infected patients. J Acquir Immune Defic Syndr 2005;
39:401-5.
23A.62 European Medicines Agency (EMA). European assessment report (EPAR). Sebivo, summary of product
characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000713/WC500049337.pdf. Accessed on August 31 st 2010.
23A.63 Kim JW et al. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother
2006;40:472-8.
23A.64 Lui YY et al. Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev Anti Infect Ther
2009;7:259-68.
23A.65 Lai CL et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;
357:2576-88.
23A.66 Colman PM. Zanamivir: an influenza virus neuraminidase inhibitor. Expert Rev Anti Infect Ther
2005;3:191-9.
23A.67 Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007;79:1577-86.
23A.68 Centers for Disease Control and Prevention (CDC). Neuraminidase inhibitors for treatment of influenza
A and B infections. Morb Mortal Wkly Rep 1999;48(RR-14):1-9.
23A.69 Gubareva LV et al. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827-35.